Skip to main content

Table 5 Known group validity testing: effect sizes of the differences between the prostate and the testicular cancer samples

From: International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer

PCa versus TCa survivors

SF36: Physical Functioning

0.82

SF36: Role-Physical

0.73

SF36: Bodily Pain

0.69

SF36: General Health

0.51

SF36: Vitality

0.10

SF36: Social Functioning

0.23

SF36: Role-Emotional

0.48

SF36: Mental Health

0.25

QLQ-C30: Global health status/QoL

0.49

QLQ-C30: Physical Function

0.67

QLQ-C30: Role Function

0.44

QLQ-C30: Emotional Function

0.01

QLQ-C30: Cognitive Function

0.40

QLQ-C30: Social Function

0.33

QLQ-C30: Fatigue

0.06

QLQ-C30: Nausea / vomiting

−0.16

QLQ-C30: Pain

0.30

QLQ-C30: Dyspnoea

0.29

QLQ-C30: Insomnia

0.18

QLQ-C30: Appetite loss

0.01

QLQ-C30: Constipation

0.31

QLQ-C30: Diarrhoea

0.05

QLQ-C30: Financial problems

−0.02

IOC: Appearance concerns

−0.03

IOC: Body change concerns

0.38

IOC: Life interferences

0.45

IOC: Worry

−0.01

IOC: Negative Impact Scale

0.21

  1. Effect sizes are displayed in bold in those cases where the known groups differed significantly (p ≤ .05). PCa prostate cancer, TCa testicular cancer. A positive effect size reflects better HRQoL in TCa survivors